Cover Image

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer

Non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions (EGFRex20ins) is relatively resistant to the existing EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is a novel TKI that selectively targets EGFRex20ins and has demonstrated therapeutic efficacy in pretreated patients with tu...

Full description

Saved in:
Bibliographic Details
Main Authors: Kian, Waleed (Author) , Christopoulos, Petros (Author) , Remilah, Areen A. (Author) , Levison, Esther (Author) , Dudnik, Elizabeth (Author) , Shalata, Walid (Author) , Krayim, Bilal (Author) , Marei, Ranin (Author) , Yakobson, Alexander (Author) , Faehling, Martin (Author) , Kahala, Dolev (Author) , Sara Granot, Inbal (Author) , Levitas, Dina (Author) , Peled, Nir (Author) , Roisman, Laila C. (Author)
Format: Article (Journal)
Language:English
Published: 20 September 2022
In: Frontiers in oncology
Year: 2022, Volume: 12, Pages: 1-9
ISSN:2234-943X
DOI:10.3389/fonc.2022.1010311
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.3389/fonc.2022.1010311
Verlag, lizenzpflichtig, Volltext: https://www.frontiersin.org/articles/10.3389/fonc.2022.1010311
Get full text
Author Notes:Waleed Kian, Petros Christopoulos, Areen A. Remilah, Esther Levison, Elizabeth Dudnik, Walid Shalata, Bilal Krayim, Ranin Marei, Alexander Yakobson, Martin Faehling, Dolev Kahala, Inbal Sara Granot, Dina Levitas, Nir Peled and Laila C. Roisman

MARC

LEADER 00000caa a2200000 c 4500
001 1824502621
003 DE-627
005 20230525082556.0
007 cr uuu---uuuuu
008 221206s2022 xx |||||o 00| ||eng c
024 7 |a 10.3389/fonc.2022.1010311  |2 doi 
035 |a (DE-627)1824502621 
035 |a (DE-599)KXP1824502621 
035 |a (OCoLC)1361670189 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Kian, Waleed  |e VerfasserIn  |0 (DE-588)1274752825  |0 (DE-627)1824503814  |4 aut 
245 1 0 |a Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer  |c Waleed Kian, Petros Christopoulos, Areen A. Remilah, Esther Levison, Elizabeth Dudnik, Walid Shalata, Bilal Krayim, Ranin Marei, Alexander Yakobson, Martin Faehling, Dolev Kahala, Inbal Sara Granot, Dina Levitas, Nir Peled and Laila C. Roisman 
264 1 |c 20 September 2022 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 06.12.2022 
520 |a Non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions (EGFRex20ins) is relatively resistant to the existing EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is a novel TKI that selectively targets EGFRex20ins and has demonstrated therapeutic efficacy in pretreated patients with tumors harboring these mutations. 
700 1 |a Christopoulos, Petros  |d 1977-  |e VerfasserIn  |0 (DE-588)138659702  |0 (DE-627)604886756  |0 (DE-576)308488067  |4 aut 
700 1 |a Remilah, Areen A.  |e VerfasserIn  |4 aut 
700 1 |a Levison, Esther  |e VerfasserIn  |4 aut 
700 1 |a Dudnik, Elizabeth  |e VerfasserIn  |4 aut 
700 1 |a Shalata, Walid  |e VerfasserIn  |4 aut 
700 1 |a Krayim, Bilal  |e VerfasserIn  |4 aut 
700 1 |a Marei, Ranin  |e VerfasserIn  |4 aut 
700 1 |a Yakobson, Alexander  |e VerfasserIn  |4 aut 
700 1 |a Faehling, Martin  |e VerfasserIn  |4 aut 
700 1 |a Kahala, Dolev  |e VerfasserIn  |4 aut 
700 1 |a Sara Granot, Inbal  |e VerfasserIn  |4 aut 
700 1 |a Levitas, Dina  |e VerfasserIn  |4 aut 
700 1 |a Peled, Nir  |e VerfasserIn  |4 aut 
700 1 |a Roisman, Laila C.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Frontiers in oncology  |d Lausanne : Frontiers Media, 2011  |g 12(2022) vom: Sept., Artikel-ID 1010311, Seite 1-9  |h Online-Ressource  |w (DE-627)684965518  |w (DE-600)2649216-7  |w (DE-576)35841184X  |x 2234-943X  |7 nnas  |a Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer 
773 1 8 |g volume:12  |g year:2022  |g month:09  |g elocationid:1010311  |g pages:1-9  |g extent:9  |a Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer 
856 4 0 |u https://doi.org/10.3389/fonc.2022.1010311  |x Resolving-System  |x Verlag  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.frontiersin.org/articles/10.3389/fonc.2022.1010311  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20221206 
993 |a Article 
994 |a 2022 
998 |g 138659702  |a Christopoulos, Petros  |m 138659702:Christopoulos, Petros  |d 910000  |d 950000  |d 950900  |e 910000PC138659702  |e 950000PC138659702  |e 950900PC138659702  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 2 
999 |a KXP-PPN1824502621  |e 4225333752 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title":"Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer","title_sort":"Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer"}],"id":{"doi":["10.3389/fonc.2022.1010311"],"eki":["1824502621"]},"recId":"1824502621","note":["Gesehen am 06.12.2022"],"language":["eng"],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"20 September 2022"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"roleDisplay":"VerfasserIn","family":"Kian","given":"Waleed","role":"aut","display":"Kian, Waleed"},{"family":"Christopoulos","roleDisplay":"VerfasserIn","role":"aut","display":"Christopoulos, Petros","given":"Petros"},{"family":"Remilah","roleDisplay":"VerfasserIn","given":"Areen A.","display":"Remilah, Areen A.","role":"aut"},{"family":"Levison","roleDisplay":"VerfasserIn","display":"Levison, Esther","role":"aut","given":"Esther"},{"family":"Dudnik","roleDisplay":"VerfasserIn","given":"Elizabeth","role":"aut","display":"Dudnik, Elizabeth"},{"family":"Shalata","roleDisplay":"VerfasserIn","display":"Shalata, Walid","role":"aut","given":"Walid"},{"display":"Krayim, Bilal","role":"aut","given":"Bilal","roleDisplay":"VerfasserIn","family":"Krayim"},{"family":"Marei","roleDisplay":"VerfasserIn","given":"Ranin","role":"aut","display":"Marei, Ranin"},{"given":"Alexander","display":"Yakobson, Alexander","role":"aut","roleDisplay":"VerfasserIn","family":"Yakobson"},{"roleDisplay":"VerfasserIn","family":"Faehling","given":"Martin","display":"Faehling, Martin","role":"aut"},{"given":"Dolev","role":"aut","display":"Kahala, Dolev","roleDisplay":"VerfasserIn","family":"Kahala"},{"display":"Sara Granot, Inbal","role":"aut","given":"Inbal","family":"Sara Granot","roleDisplay":"VerfasserIn"},{"family":"Levitas","roleDisplay":"VerfasserIn","given":"Dina","display":"Levitas, Dina","role":"aut"},{"display":"Peled, Nir","role":"aut","given":"Nir","roleDisplay":"VerfasserIn","family":"Peled"},{"role":"aut","display":"Roisman, Laila C.","given":"Laila C.","roleDisplay":"VerfasserIn","family":"Roisman"}],"name":{"displayForm":["Waleed Kian, Petros Christopoulos, Areen A. Remilah, Esther Levison, Elizabeth Dudnik, Walid Shalata, Bilal Krayim, Ranin Marei, Alexander Yakobson, Martin Faehling, Dolev Kahala, Inbal Sara Granot, Dina Levitas, Nir Peled and Laila C. Roisman"]},"physDesc":[{"extent":"9 S."}],"relHost":[{"disp":"Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancerFrontiers in oncology","note":["Gesehen am 07.11.13"],"title":[{"title_sort":"Frontiers in oncology","title":"Frontiers in oncology"}],"id":{"zdb":["2649216-7"],"eki":["684965518"],"issn":["2234-943X"]},"part":{"text":"12(2022) vom: Sept., Artikel-ID 1010311, Seite 1-9","volume":"12","extent":"9","year":"2022","pages":"1-9"},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2011","publisherPlace":"Lausanne","dateIssuedDisp":"2011-","publisher":"Frontiers Media"}],"pubHistory":["2011 -"],"recId":"684965518"}]} 
SRT |a KIANWALEEDREALWORLDE2020 

Similar Items